Skip to content

IEMbase 0333: MOGS/GCS1-related glucosidase 1 deficiency

Scope

Field Value
IEMbase ID 333
Nosology 18.1.2.01
Gene MOGS
External IDs OMIM:606056
Generated mapping UNMAPPED
Candidate DisMech targets Reject Gaucher_Disease.yaml
Review date 2026-07-07

IEMbase phenotype signal

IEMbase represents GCS1-CDG/CDG-IIb, caused by MOGS/glucosidase I deficiency. Characteristic rows include alopecia areata, high-arched palate, abnormal brain evoked response audiometry, burst-suppression EEG, epilepsy, facial dysmorphism, overlapping fingers, hepatomegaly, hypokinesia, hypoplastic labia majora, hypotonia, long eyelashes, myelinating neuropathy, respiratory failure, short palpebral fissures, and abnormal visual evoked potentials. Additional clinical rows include apnea, broad nose, developmental delay, gastric tube feeding, prominent occiput, retrognathia, and short palpebral fissures.

The biochemical rows are sparse but distinctive: abnormal serum sialotransferrins, increased urinary tetraglucoside, and decreased immunoglobulins. No treatment rows are present.

DisMech phenotype coverage

The Gaucher disease candidate is a lexical false positive around glucosidase terminology. Gaucher disease is a lysosomal storage disease caused by GBA1 beta-glucocerebrosidase deficiency, with glucosylceramide/glucosylsphingosine storage, hepatosplenomegaly, cytopenias, bone disease, and ERT/SRT treatment logic. It is not MOGS/glucosidase I deficiency and does not cover CDG-IIb.

Other local glycosylation entries and the CDG module provide family context, but no standalone MOGS/GCS1-CDG entry exists.

Concordance and completeness

Judgement: true local disease gap; reject the Gaucher candidate.

IEMbase points to a distinct type II CDG with neurologic, respiratory, craniofacial, immunologic, sensory-evoked-potential, and tetraglucoside signals. The shared words "glucosidase" and "hepatomegaly" are not enough to map this record to Gaucher disease.

Curation actions

  • Add a standalone MOGS/GCS1-CDG target before treating this record as mapped.
  • Do not map this record to Gaucher disease or other lysosomal glucosidase disorders.
  • Preserve urinary tetraglucoside, immunoglobulins, burst-suppression EEG, evoked-potential abnormalities, respiratory failure/apnea, and myelinating neuropathy as future-curation prompts.